Rapport Therapeutics (NASDAQ:RAPP) Insider Sells $197,338.35 in Stock

Rapport Therapeutics, Inc. (NASDAQ:RAPP) insider David Bredt sold 6,567 shares of the business’s stock in a transaction on Wednesday, December 31st. The shares were sold at an average price of $30.05, for a total transaction of $197,338.35. Following the sale, the insider directly owned 404,075 shares in the company, valued at approximately $12,142,453.75. This trade represents a 1.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

David Bredt also recently made the following trade(s):

• On Monday, December 15th, David Bredt sold 8,500 shares of Rapport Therapeutics stock. The shares were sold at an average price of $30.02, for a total value of $255,170.00.
• On Monday, November 17th, David Bredt sold 8,500 shares of Rapport Therapeutics stock. The stock was sold at an average price of $25.19, for a total value of $214,115.00.
• On Wednesday, October 15th, David Bredt sold 8,500 shares of Rapport Therapeutics stock. The shares were sold at an average price of $25.79, for a total value of $219,215.00.

Rapport Therapeutics Stock Down 2.1%

Shares of RAPP traded down $0.59 during trading hours on Monday, reaching $27.52. The company’s stock had a trading volume of 245,586 shares, compared to its average volume of 357,843. The company has a 50 day moving average of $28.24 and a two-hundred day moving average of $22.20. The firm has a market cap of $1.31 billion, a price-to-earnings ratio of -10.15 and a beta of 1.63. Rapport Therapeutics, Inc. has a 1-year low of $6.43 and a 1-year high of $42.27.

Rapport Therapeutics (NASDAQ:RAPP) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.71) EPS for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.06. As a group, analysts forecast that Rapport Therapeutics, Inc. will post -3.65 EPS for the current fiscal year.

Analysts Set New Price Targets

RAPP has been the subject of several research reports. Wells Fargo & Company set a $51.00 price target on Rapport Therapeutics in a report on Friday, December 19th. HC Wainwright boosted their price target on Rapport Therapeutics from $34.00 to $40.00 and gave the stock a “buy” rating in a research report on Tuesday, December 9th. The Goldman Sachs Group reissued a “buy” rating on shares of Rapport Therapeutics in a research report on Friday, December 19th. Citizens Jmp upped their price target on shares of Rapport Therapeutics from $77.00 to $80.00 and gave the company a “market outperform” rating in a report on Friday, November 7th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $47.00 price target on shares of Rapport Therapeutics in a research report on Monday, December 8th. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $48.33.

Institutional Investors Weigh In On Rapport Therapeutics

A number of institutional investors have recently added to or reduced their stakes in RAPP. Strs Ohio lifted its position in shares of Rapport Therapeutics by 23.5% in the 3rd quarter. Strs Ohio now owns 2,100 shares of the company’s stock worth $62,000 after acquiring an additional 400 shares during the period. Creative Planning raised its position in Rapport Therapeutics by 12.8% in the third quarter. Creative Planning now owns 11,959 shares of the company’s stock worth $355,000 after purchasing an additional 1,357 shares in the last quarter. Russell Investments Group Ltd. bought a new position in Rapport Therapeutics during the third quarter worth about $43,000. Two Sigma Investments LP raised its holdings in shares of Rapport Therapeutics by 8.9% in the 3rd quarter. Two Sigma Investments LP now owns 21,500 shares of the company’s stock worth $639,000 after buying an additional 1,757 shares in the last quarter. Finally, Acuta Capital Partners LLC raised its holdings in shares of Rapport Therapeutics by 22.0% in the 2nd quarter. Acuta Capital Partners LLC now owns 20,000 shares of the company’s stock worth $227,000 after buying an additional 3,600 shares in the last quarter.

Rapport Therapeutics Company Profile

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.